1. Torre-Amione G, Beuchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A Highly Immunogenic Tumor Transfected with a Murine Transforming Growth Factor Type beta 1 cDNA Escapes Immune Surveillance. Proceedings of the National Academy of Science, U.S.A. 87:1486-1490, 1990. 2. Teng MN, Park BH, Koeppen HKW, Tracey KJ, Fendly BM, Schreiber H. Long-term Inhibition of Tumor Growth by Tumor Necrosis Factor in the Absence of Cachexia or T -cell Immunity. Proceedings of the National Academy of Science, U.S.A. 88:3535-3539, 1991. 3. Koeppen HKW, Singh S, Strauss HJ, Park BH, Rowley DA, Schreiber H. CD4 Positive and B Lymphocytes in Transplantation Immunity. I. Promotion of Tumor Allograft Rejection through Elimination of CD4-Positive Lymphocytes. Transplantation 55: 1349-1355, 1993. 4. Park BH, Lavi E, Blank K, Gaulton GN. Intracerebral Hemorrhages and Syncytium Formation Induced by Endothelial Cell Infection with a Murine Leukemia Virus. Journal of Virology 67:6015-6024, 1993. 5. Park BH, Lavi E, Stieber A, Gaulton GN. Pathogenesis of Cerebral Infarction and Hemorrhage induced by a Murine Leukemia Virus. Laboratory Investigation 71:78-85, 1994. 6. Park BH, Lavi E, Gaulton GN. Intracerebral Hemorrhages and Infarction Induced by a Murine Leukemia Virus are Influenced by Host Determinants Within Endothelial Cells. Virology 203:393-396, 1994. 7. Park BH, Matuschke B, Lavi E, Gaulton GN. A Point Mutation in the Env Gene of a Murine Leukemia Virus Induces Syncytium Formation and Neurologic Disease. Journal of Virology 68:7516-7524, 1994. 8. Marshall DJ, Park BH, Korostoff.JM, Gaulton GN. Manipulation of the Immune Response by Foreign Gene Expression in the Thymus. Leukemia 9:S128-S132, 1995. 9. Zhang L, Yu J, Park BH, Kinzler K, Vogelstein B. Role of BAX in the Apoptotic Response to Anticancer Agents. Science 290:989-992, 2000. 10. Park BH, Vogelstein B, Kinzler K. Genetic Disruption of PPAR Delta Decreases the Tumorigenicity of Human Colon Cancer Cells. Proceedings of the National Academy of Science, U.S.A. 98:2598-2603, 2001. 11. Rhee I, Bachmann KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3B Cooperate to Silence Genes in Human Cancer Cells. Nature 416:552-556, 2002. 12. Bachman KE,* Park BH,* Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW and Vogelstein B. The role of histone codes and DNA methylation in silencing tumor suppressor genes, Cancer Cell 3:89-95, 2003. *Contributed equally to this work. 13. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P and Park BH. p21 mediates the growth response to TGF-beta in human epithelial cells, Cancer Biology and Therapy, 3:221-225, 2004. 14. Bachman KE , Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE and Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers, Cancer Biology and Therapy 3:772-775, 2004. 15. Bachman KE, Sager J, Cheong I, Catto M, Bardelli A, Park BH, Vogelstein B, Carotti A, Kinzler KW and Lengauer C. Identification of compounds that inhibit growth of PhIP resistant cancer cells, Molecular Cancer Therapeutics, 4(6):1026-30, Jun 2005. 16. Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, Blair B, Brenner K and Davidson NE. Protein phosphatase 2A (PP2A) regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability, J. Biol. Chem. 280(33):29519-24, Aug.19 2005. 17. Huang Y, Keen JC, Pledgie A, Marton LJ, Zhu T, Sukumar S, Park BH, Blair B, Brenner K, Casero RA Jr, Davidson NE. Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. J. Biol. Chem. 281(28):19055-63, Jul 14, 2006. 18. Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo MI, Bachman KE, and Park BH. Physiologic Estrogen Receptor Alpha Signaling in Non-tumorigenic Human Mammary Epithelial Cells, Breast Cancer Res Treat, 99(1):23-33, Sept. 2006. 19. Karakas B, Weeraratna A, Abukhdeir A, Blair BG, Konishi H, Arena S, Becker K, Wood W, Argani P, De Marzo AM, Bachman KE and Park BH. Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells, Oncogene, 25(40):5561-9, Sep 7, 2006. 20. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber T, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The Consensus Coding Sequences of Human Breast and Colorectal Cancers, Science, Oct 13;314(5797):268-74, 2006. 21. Weiss M.B., Vitolo M.I., Baerenfaller K., Marra G., Park B.H., Bachman K.E. Persistent mismatch repair deficiency following targeted correction of hMLH1. Cancer Gene Therapy, Jan;14(1):98-104, 2007. 22. Karakas B, Weeraratna A, Abukhdeir A, Konishi H, Gustin J, Vitolo MI, Bachman KE, Park BH. p21 gene knock down does not identify genetic effectors seen with gene knock out, Cancer Biology and Therapy, Mar 26;6(7) 2007. 23. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen Receptor α Mediates Breast Cancer Cells Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death, Cancer Research, Jun 1;67(11):5337-44, 2007 24. Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier Y, Bachman KE, Park BH. Knock in of mutant K-ras in non-tumorigenic human epithelial cells as a new model for studying K-ras mediated transformation, Cancer Research Sep15;67(18):8460-7, 2007. 25. Konishi H, Lauring J, Garay JP, Karakas B, Abukhdeir AM, Gustin JP, Konishi Y, Park BH. A PCR-based high-throughput screen with multi-round sample pooling: application to somatic cell gene targeting, Nature Protocols 2(11):2865-74, 2007. 26. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers, Science Nov 16;318(5853):1108-13, 2007. 27. Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui M and Park BH. The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity, Blood Jan 15;111(2):856-64, 2008. 28. Abukhdeir A, Vitolo M, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin J, Lauring J, Garay J, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen stimulated growth of breast cancer due to p21 loss, Proceedings of the National Academy of Science, U.S.A. Jan 8;105(1):288-93, 2008. 29. Leary R, Lin J, Cummins J, Boca S, Wood L, Parsons D, Jones S, Sjoblom T, Park BH, Parsons R, Willis J, Dawson D, Willson J, Nikolskaya T ,Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio L, Wang TL, Markowitz S, Parmigiani G, Kinzler K, Vogelstein B and Velculescu V. Dramatic changes in copy number are a major mechanism for gene activation and inactivation in breast and colorectal cancers, Proceedings of the National Academy of Science, U.S.A. Oct 21;105(42):16224-9, 2008. 30. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate May 1;69(6):603-9, 2009. 31. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knock in of mutant PIK3CA activates multiple oncogenic pathways. Proceedings of the National Academy of Science, U.S.A, Feb 24;106(8):2835-40, 2009. 32. Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, Martin SS, Weber DJ, Bachman KE. Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in Human Mammary Epithelial Cells. Cancer Research, Nov 1;69(21):8275-83, 2009. 33. Karnan S, Mohseni M, Konishi Y, Tamaki A, Hosokawa Y, Park BH*, Konishi H*. Controversial BRCA1 allelotypes in commonly used breast cancer cell lines. Breast Cancer Res Treat. Jan;119(1):249-51, 2010. *Co-corresponding author. 34. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Buckhaltz P, Park BH. Knock in of the AKT1 E17K hotspot mutation in human breast epithelial cells does not recapitulate the phenotype of oncogenic PIK3CA mutations, Oncogene Apr 22;29(16):2337-45, 2010. 35. Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH*, Weber DJ*, Bachman KE*. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response, Oncogene, Aug 19;29(33):4715-24, 2010. *Co-corresponding author. 36. Colak D, Chisti MA, Al-Bakheet A, Al-Qahtani A, Shoukri MM, Goyns MH, Ozand PT, Quackenbush J, Park BH, Kaya N. Integrative and Comparative Genomics Analysis of Early Hepatocellular Carcinoma Differentiated from Liver Regeneration in Young and Old, Molecular Cancer, Jun 12;9:146, 2010. 37. Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring J, Cosgrove DP, Garay JP, Konishi H, Tamaki A, Mohseni M, Wang GM, Cidado J, Jelovac D, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells, Cancer Biology and Therapy, Feb 1;11(3):35-44, 2011. 38. Lewis GH, Subhawong AP, Nassar H, Vang R, Illei P, Park BH, and Argani P. Relationship between Molecular Subtype of Invasive Breast Carcinoma (IBC) and Expression of Gross Cystic Disease Fluid Protein 15 (GCDFP) and Mammaglobin (MGB), American Journal of Clinical Pathology, Apr;135(4):587-91, 2011. 39. Li H, Keeton A, Maddox C, Rasmussen L, Hobrath J, White EL, Piazza GA, Kim JS, Vitolo M, Park BH, Waldman T. A High Throughput Screen with Isogenic PTEN+/+ and PTEN-/- Cells Identifies CID1340132 As a Novel Compound That Induces Apoptosis in PTEN and PIK3CA Mutant Human Cancer Cells, J Biomol Screen, Apr;16(4):383-93, 2011. 40. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients, Clinical Cancer Research, Oct 15;17(20):6563-73, 2011. 41. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir, K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy C, Hosokawa Y, Gabrielson E, Meeker A, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cell, Proceedings of the National Academy of Science, U.S.A, Oct 25;108(43):17773-8, 2011. 42. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcie BA, Li W, Gozani O. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming, Molecular Cell, Nov 18;44(4):609-20, 2011. 43. Cimino-Mathews A, Hicks JL, Illei PB, Halushka MK, Fetting JH, De Marzo AM, Park BH, Argani P. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Human Pathology, Jul;43(7):1003-11, 2012. 44. Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH. The growth response to androgen receptor signaling in ERα negative human breast cells is dependent on p21 and mediated by MAP kinase activation, Breast Cancer Research, Feb 9;14(1):R27, 2012. 45. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH. Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood and Implications for Targeted Therapy, Clinical Cancer Research, Jun 15;18(12):3462-9, 2012. 46. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome, Proceedings of the National Academy of Science, U.S.A, Sep 11;109(37):14977-82, 2012. 47. Cimino-Mathews A, Subhawong AP, Elwood H, Nassar H, Sharma R, Park BH, Taube J, Illei PB, Argani P. Neural crest transcription factor Sox10 is preferentially expressed in triple negative and metaplastic breast carcinomas, Human Pathology, Jun;44(6):959-65, 2013. 48. Jin L, Hanigan CL, Wu Y, Wang W, Park BH, Woster PM, Casero RC. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. Biochemical Journal, Jan 15;449(2):459-68, 2013. 49. Cimino-Mathews A, Subhawong AP, Elwood H, Nassar H, Sharma R, Park BH, Taube J, Illei PB, Argani P. GATA3 Expression in Breast Carcinoma: Utility in Triple Negative, Sarcomatoid and Metastatic Carcinomas, Human Pathology, Jul;44(7):1341-9, 2013. 50. Wang GM, Wong HY, Konishi H, Abukhdeir A, Gustin JP, Rosen M, Denmeade S, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran R, Karnan S, Hosokawa Y, Argani P, Lauring J, Park BH. A single mutant KRAS allele cooperates with mutant PIK3CA in human epithelial cells to induce transformation, Cancer Research, Jun 1;73(11):3248-61, 2013. 51. Colak D, Nofal A, Nirmal M, Jeprel H, AlBakheet A, Eldali A, AL-Tweigeri T, Tulbah A, Ajarim D, Al Malik O, Inan MS , Kaya N, Park BH, Bin Amer SM. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women, PLOS One, May 21;8(5):e63204, 2013. 52. Ghosh S, Varela L, Sood A, Park BH, and Lotan T. mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss, Cancer Research, Aug 15;73(16):5218-31, 2013. 53. Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Park BH, Lauring J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system, Clinical Cancer Research. Oct 1;19(19):5413-22, 2013. 54. Karakas B, Colak D, Kaya N, Ghebeh H, Al-Qasem A, Hendrayan F, Toulimat M, Al-Tweigeri T, Park BH, Aboussekhra A. Prevalence of PIK3CA Mutations and the SNP rs17849079 in Arab Breast Cancer Patients, Cancer Biology and Therapy, Oct 1;14(10):888-96, 2013. 55. Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH*Wolff AC*. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers, Human Pathology, Apr;45(4):880-3, 2014. *co-corresponding senior authors. 56. Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yan Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer PS, Lal A. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the miR-183-96-182 cluster. MolCellBio. Feb;34(3):533-50, 2014. 57. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels M, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC* and Park BH*. Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer, Clinical Cancer Research, May 15;20(10):2643-50, 2014, *co-corresponding senior authors. 58. Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkin DP. BRCA1 deficiency exacerbates estrogen induced DNA damage and genomic instability. Cancer Research, May 15;74(10):2773-84, 2014. 59. Forde PM, Cochran RL, Boikos SA, Zabransky DJ, Beaver JA, MeyerCF, Thornton KA, Montgomery EA, Lidor AO, Donehower RC and Park BH. Familial Gastrointestinal Stromal Tumor with Loss-of-Heterozygosity and Amplification of Mutant KIT, J.Clin.Oncol. May 27, 2014. 60. Cochran RL, Cravero K, Chu D, Erlanger B, Valda Toro P, Beaver JA, Zabransky DJ, Wong HY, Cidado J, Croessmann S, Parsons H, Kim M, Wheelan SJ, Argani P and Park BH. Analysis of BRCA2 loss-of-heterozygosity in tumor tissue using droplet digital PCR. Human Pathology, Jul;45(7):1546-50, 2014. 61. Nguyen HN, Yang JM, Afkari Y, Park BH, Sesaki H, Devreotes PN, Iijima M. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Proc Natl Acad Sci U S A. Jun 16, 2014. 62. Wu, X., Renuse, S., Sahasrabuddhe, N. A.., Zahari, M. S., Chaerkady, R., Kim, M. S., Nirujogi, R. S., Mohseni, M., Kumar, P., Raju, R., Zhong, J., Yang, J., Neiswinger, J., Jeong, J. S., Newman, R., Powers, M. A., Somani, B. L., Gabrielson, E., Sukumar, S., Stearns, V., Qian, J., Zhu, H., Vogelstein, B., Park, B. H.* and Pandey, A.*. Activation of diverse signaling pathways by oncogenic PIK3CA mutations. Nature Communications. Sep 23;5:496, 2014, *co-corresponding senior authors. 63. Nguyen HN, Yang JM, Rahdar M, Keniry M, Parsons R, Park BH, Sesaki H, Devreotes PN and Iijima M. A New Class of Cancer-Associated PTEN Mutations Defined by Membrane Translocation Defects. Oncogene, Sep 29, 2014. 64. Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir A, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A. Dec 9;111(49):17606-11, 2014. 65. Blair BG, Wu X, Zahari MS, Mohseni M, Cidado J, Wong HY, Beaver JA, Cochran RL, Zabransky DJ, Croessmann S, Chu D, Toro PV, Cravero K, Pandey A, Park BH. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. Jan;15(2-3):318-26, 2015. 66. VandenBussche C, Cimino-Mathews A, Park BH, Emens LA, TsangarisTN, Argani P. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. Am.J.Surg.Path. Jul;39(7):939-947, 2015. 67. Young CD , Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola N, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O’Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook R and Arteaga1 CL. Activating PIK3CA mutations induce an EGFR/ERK paracrine signaling axis in basal-like breast cancer. Molecular & Cellular Proteomics. Jul;14(7):1959-76, 2015. 68. Jhaveri TZ, Woo J, Shang X, Park BH, Gabrielson E. AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget. Jun 20;6(17):14754-65, 2015. 69. Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J and Park BH. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget. Sep 22;6(28):25240-51, 2015. 70. Valda Toro P, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ, Lauring J, Park BH. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin. Biochem. Oct;48(15):993-8, 2015. 71. Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, Mohseni M, Rosen DM, Scharpf R, Cidado J, Cochran RL, Parsons H, Dalton WB, Erlanger B, Button B, Cravero K, Kyker-Snowman K, Beaver JA, Kachhap S, Hurley PJ, Lauring J, Park BH. NDRG1 links p53 with proliferation mediated centrosome homeostasis and genome stability. Proc Natl Acad Sci U S A. Sep 15;112(37):11583-8, 2015. 72. Zahari MS, Wu X, Blair BG, Pinto SM, Nirujogi RS, Jelinek CA, Malhotra R, Kim MS, Park BH, Pandey A. Activating mutations in PIK3CA lead to widespread modulation of the tyrosine phosphoproteome. J Proteome Res. Sep 4;14(9):3882-91, 2015. 73. Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons H, Dalton BD, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan A, Schott A, Robertson D, Jacks KS, Lauring J, Hurley P, Hayes DF, Rae JM and Park BH. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clinical Cancer Research, Feb 15;22(4):993-9, 2016. 74. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Brewer MR, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons H, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. Nov 10;112(45), 2015. 75. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research, Jan 15;22(2):448-58, 2016. 76. Wong HY, Wang GM, Croessmann S, Zabransky DJ, Chu D, Garay JP, Cidado J, Cochran RC, Beaver JA, Aggarwal A, Liu ML, Argani P, Meeker A, Hurley PJ, Lauring J, Park BH. TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Oncotarget, Dec 29;6(42):44927-40, 2015. 77. Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, Christenson ES, Medford A, Mattox A, De Marzo AM, Argani P, Chawla A, Hurley PJ, Lauring J, Park BH. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget, Feb 2;7(5):6281-93, 2016. 78. Argani P, Lee J, Netto GJ, Zheng G, Tseh-Lin M, Park BH. Frequent BRAF V600E mutations in metanephric stromal tumor. Am J Surg Path, May;40(5):719-22, 2016. 79. Hayashi M, Chu D, Meyer CF, Llosa NJ, McCarty G, Morris CD, Levin AS, Wolinsky JP, Albert CM, Steppan DA, Park BH, Loeb DM. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer. Jun 28, 2016. 80. VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y. Am J Surg Pathol. Aug;40(8):1090-9, 2016. 81. Parsons HA, Beaver JA, Cimino-Mathews A, Ali S, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark T, Gocke C, Jeter S, Kennedy M, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V and Park BH. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer, Clinical Cancer Research, Jan 15;23(2):379-386, 2016. 82. Lee J, Axilbund J, Dalton BD, Laheru D, Watkins S, Chu D, Cravero K, Button B, Kyker-Snowman K, Waters I, Gocke C, Lauring J and Park BH. A polycythemia vera JAK2 mutation masquerading as a germline cancer mutation in a patient with duodenal cancer, The Journal of the National Comprehensive Cancer Network, Dec;14(12):1495-1498, 2016. 83. Kim H, Umbricht C, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Christina Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller D, Armstrong D, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC*, Cope L* Optimizing the Use of Gene Expression Profiling in Early Stage Breast Cancer, Journal of Clinical Oncology, Dec 20;34(36):4390-4397, 2016. 84. Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CB. ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Oncotarget, Oct 18, 2016. 85. Goldstein A, Valda Toro P, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ. Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, Feb 28;8(9):15651-15662, 2017. 86. Croessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, Cochran RL, Dalton WB, Erlanger B, Cravero K, Button B, Kyker-Snowman K, Hurley PJ, Lauring J, Park BH. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Res Treat, Apr;162(3):451-464, 2017. 87. Dalton B, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson E, Slater SA, Ensminger J, Parsons HA, Park BH and Lauring J. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precision Oncology, 1, 1-19, 2017. 88. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen EEW, Lippman SM, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. Aug 15;23(16):4716-4723, 2017. 89. Avigdor B, Beierl K, Gocke CD, Zabransky D, Cravero K, Kyker-Snowman K, Button B, Chu D, Croessmann S, Cochran RL, Connolly R, Park BH*, Wheelan SJ*, Cimino-Mathews A*. Whole exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component. Clin Cancer Res. Aug 15;23(16):4875-4884, 2017. *Co-corresponding author. 90. Christenson ES, Dalton WB, Chu D, Waters I, Cravero K, Zabransky DJ, DeZern A, Park BH. A single nucleotide polymorphism leading to a false allelic fraction by droplet digital PCR. Clin. Chem. Aug;63(8):1370-1376, 2017. 91. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw C, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. Sep 1;23(17):5123-5134, 2017. 92. Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res. May 23;19(1):60, 2017. 93. VanLiere Canzoniero J, Cravero K, Park BH. The impact of collisions on the ability to detect rare mutant alleles using barcode-type next generation sequencing techniques. Cancer Informatics. July 10:16, 2017. 94. André F, Arnedos M, Baras AS, Baselga J, Bedard PL, Berger MF, Bierkens M, Calvo F, Cerami E, Chakravarty D, Dang KK, Davidson NE, Del Vecchio Fitz C, Dogan S, DuBois RN, Ducar MD, Futreal PA, Gao J, Garcia F, Gardos S, Gocke CD, Gross BE, Guinney J, Heins ZJ, Hintzen S, Horlings H, Hudeček J, Hyman DM, Kamel-Reid S, Kandoth C, Kinyua W, Kumari P, Kundra R, Ladanyi M, Lefebvre C, LeNoue-Newton ML, Lepisto EM, Levy MA, Lindeman NI, Lindsay J, Liu D, Lu Z, MacConaill LE, Maurer I, Maxwell DS, Meijer GA, Meric-Bernstam F, Micheel CM, Miller C, Mills G, Moore ND, Nederlof PM, Omberg L, Orechia JA, Park BH, Pugh TJ, Reardon B, Rollins BJ, Routbort MJ, Sawyers CL, Schrag D, Schultz N, Shaw KRM, Shivdasani P, Siu LL, Solit DB, Sonke GS, Soria JC, Sripakdeevong P, Stickle NH, Stricker TP, Sweeney SM, Taylor BS, Ten Hoeve JJ, Thomas SB, Van Allen EM, Van 't Veer LJ, van de Velde T, van Tinteren H, Velculescu VE, Virtanen C, Voest EE, Wang LL, Wathoo C, Watt S, Yu C, Yu TV, Yu E, Zehir A, Zhang H. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery. Aug;7(8):818-831, 2017. 95. J.H. Chung D. Pavlick R. Hartmaier A.B. Schrock L. Young B. Forcier P. Ye M.K. Levin H. Burris L.M. Gay A.D. Hoffman P.J. Stephens G.M. Frampton D.M. Lipson D.M. Nguyen S. Ganesan B.H. Park L.T. Vahdat B. Leyland-Jones T.I. Mughal L. Pusztai J. O’Shaughnessy V.A. Miller J.S. Ross S.M. Ali. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Annals of Oncology. In press. 2017. 96. Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, Gundem G, Tian K, Geiger H, Redfield K, Behr G, Benayed R, Zehir A, Hechtman JF, Darnell RB, Papaemmanuil E, Ladanyi M, Ku N, Kung AL, Baselga J, Drilon A, and Hyman DM. Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. JCO Precision Oncology, In press, 2017. 97. Zhao Y, Laws MJ, Guillen VS, Ziegler Y, Min J, Sharma A, Kim SH, Chu D, Park BH, Oesterreich S, Mao C, Shapiro DJ, Nettles KW, Katzenellenbogen JA, Katzenellenbogen BS. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. Cancer Res. Oct 15;77(20):5602-5613, 2017. 98. Li Z, Levine KM, Bahreini A, Wang P, Chu D, Park BH, Oesterreich S, Lee AV. Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells. Endocrinology. Sep 27, 2017. 99. Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Research. In press, 2017. 100. Avigdor BE, Cimino-Mathews A, DeMarzo AM, Hicks JL, Shin J, Sukumar S, Fetting J, Argani P*, Park BH*, Wheelan SJ*. Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. JCI Insight. In press, 2017. *Co-corresponding author. 101. Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Res Treat, In press, 2018. 102. Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali S, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer. Ann Oncol. 2018 Jan 19, 103. A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Kyker-Snowman K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, Wheelan SJ*, Argani P*, Park BH*. Breast Cancer Res Treat. 2018 Mar 15. *Co-corresponding author. 104. Cravero K, Medford A, Pallavajjala A, Canzoniero J, Hunter N, Chu D, Cochran RL, Waters I, Christenson ES, Kyker-Snowman K, Button B, Cole AJ, Park BH. Biotinylated Amplicon Sequencing: A method for preserving DNA samples of limited quantity. Practical Laboratory Medicine. Aug 9;12:e00108, 2018. 105. Yu L, Wang L, Mao C, Duraki D, Kim JE, Huang R, Helferich WG, Nelson ER, Park BH, Shapiro DJ. Cancer Lett. 2018 Nov 9. 106. Button B, Croessmann S, Chu D, Rosen DM, Zabransky DJ, Dalton WB, Cravero K, Kyker-Snowman K, Waters I, Karthikeyan S, Christenson ES, Donaldson J, Hunter T, Dennison L, Ramin C, May B, Roden R, Petry D, Armstrong DK, Visvanathan K, Park BH. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. Breast Cancer Res Treat. 2018 Dec 17. 107. Zhang X, Wang Y, Chiang HC, Hsieh YP, Lu C, Park BH, Jatoi I, Jin VX, Hu Y, Li R. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Breast Cancer Res. 2019; 21: 51. 108. Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan TL, Huang J, Davicioni E, An SS, Riddle RC, Thorek DL, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Res. 2019 May 23. 109. Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ. Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2019;3. 110. Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, Patil A, Zabransky DJ, Medford A, Lee J, Cole AJ, Rosen M, Thakar M, Ambinder A, Donaldson J, DeZern AE, Cravero K, Chu D, Madero-Marroquin R, Pandey A, Hurley PJ, Lauring J, Park BH. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. J Clin Invest. 2019 Aug 8;130. 111. Stuttgen K, Croessmann S, Fetting J, Stearns V, Nunes R, Connolly RM, Park BH. Pathogenic Germline Variants in Metastatic Breast Cancer Patients. JAMA Oncology, Aug 29, 2019. 112. Wang F, Reid S, Zheng W, Pal T, Meszoely I, Mayer IA, Bailey CE, Park BH, Shu XO. Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. Clin Cancer Res. 2019 Nov 20. 113. Kyker-Snowman K, Hughes RM, Yankaskas CL, Cravero K, Karthikeyan S, Button B, Waters I, Rosen DM, Dennison L, Hunter N, Donaldson J, Christenson ES, Konstantopoulos K, Hurley PJ, Croessmann S, Park BH. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res Treat. 2019 Dec 10. 114. Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, Andre F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM, Genie Consortium AP. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. Cancer Discovery. 2020 Jan 10. pii: CD-19-1209. 115. Hunter N, Croessmann S, Cravero K, Shinn D, Hurley PJ, Park BH. Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. J Natl Compr Canc Netw. 2020 Apr;18(4):375-379. 116. Laws MJ, Ziegler Y, Shahoei SH, Dey P, Kim SH, Yasuda M, Park BH, Nettles KW, Katzenellenbogen JA, Nelson ER, Katzenellenbogen BS. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors. Breast Cancer Res Treat. 2020 Jun;181(2):297-307 117. Rao S, Pitel B, Wagner AH, Boca SM, McCoy M, King I, Gupta S, Park BH, Warner JL, Chen J, Rogan PK, Chakravarty D, Griffith M, Griffith OL, Madhavan S. Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices. JCO Clin Cancer Inform. 2020 Jul;4:602-613. doi: 10.1200/CCI.19.00169. 118. Cotul EK, Zuo Q, Santaliz-Casiano A, Imir OB, Mogol AN, Tunc E, Duong K, Lee JK, Ramesh R, Odukoya E, Kesavadas MP, Ziogaite M, Smith BP, Mao C, Shapiro DJ, Park BH, Katzenellenbogen BS, Daly D, Aranda E, O'Neill JD, Walker C, Landesman Y, Madak-Erdogan Z. Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. Cancers. 2020 Aug 24;12(9):E2397. doi: 10.3390/cancers12092397. 119. Karthikeyan S, Waters IG, Dennison L, Chu D, Donaldson J, Shin DH, Rosen DM, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Pantone MV, Bergman RE, Davidson BA, Reed SC, Zabransky DJ, Cravero K, Kyker-Snowman K, Button B, Wong HY, Hurley PJ, Croessmann S*, Park B*. Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. J Clin Invest. 2021 Feb 2:143557. *Co-corresponding authors. 120. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Feb 3. doi: 10.1158/1078-0432.CCR-19-4191. 121. Christenson ES, Gizzi A, Cui J, Egleston M, Seamon KJ, DePasquale M, Orris B, Park BH, Stivers JT. Inhibition of hUNG2 Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-fluorodeoxyuridine (FdU) and Raltitrexed (RTX) but not Fluorouracil (FU). Mol Pharmacol. 2021 Apr 1; Online ahead of print. 122. Boleij A, Fathi P, Dalton W, Park B, Wu X, Huso D, Allen J, Besharati S, Anders RA, Housseau F, Mackenzie AE, Jenkins L, Milligan G, Wu S, Sears CL.. G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis. Communications Biology, 2021, vol.4: 585. 123. Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2021 May 17:JCO2100280. doi: 10.1200/JCO.21.00280. Online ahead of print. 124. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA113. J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976. Online ahead of print. 125. Zonneville J, Wang M, Alruwaili MM, Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Commun Biol. 2021 Jul 12;4(1):862. 126. Ho WJ, Croessmann S, Lin J, Phyo ZH, Charmsaz S, Danilova L, Mohan AA, Gross NE, Chen F, Dong J, Aggarwal D, Bai Y, Wang J, He J, Leatherman JM, Yarchoan M, Armstrong TD, Zaidi N, Fertig EJ, Denny JC, Park BH*, Zhang ZY*, Jaffee EM*. Systemic inhibition of PTPN22 augments anticancer immunity. J Clin Invest. 2021 Jul 20;146950. *co-corresponding author. 127. Boudreau MW, Duraki D, Wang L, Mao C, Kim JE, Henn MA, Tang B, Fanning SW, Kiefer J, Tarasow TM, Bruckheimer EM, Moreno R, Mousses S, Greene GL, Roy EJ, Park BH, Fan TM, Nelson ER, Hergenrother PJ, Shapiro DJ. A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Sci Transl Med. 2021 Jul 21;13(603):eabf1383. doi: 10.1126. 128. Jain NM, Schmalz L, Cann C, Adara Holland MBA, Travis Osterman DO, Lang K, Wiesner GL, Pal T, Lovly C, Stricker T, Micheel C, Balko JM, Johnson DB, Park BH, Iams W. Framework for Implementing and Tracking A Molecular Tumor Board at an NCI-Designated Comprehensive Cancer Center. Oncologist. Aug 14. doi: 10.1002/onco.13936. 2021 129. Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS; AACR Project GENIE Consortium. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. JAMA Oncol. 2021 Nov 4. doi: 10.1001/jamaoncol.2021.5153. 130. Sun S, Brazhnik K, Lee M, Maslov AY, Zhang Y, Huang Z, Klugman S, Park BH, Vijg J, Montagna C. Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers. J Clin Invest. 2022 Jan 13;e148113. 131. Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, Park BH, Stearns V, Wolff AC. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clin Breast Cancer. 2021 Dec 30;S1526-8209(21)00358-X. 132. Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Res. 2022 Jan 25;canres.CAN-21-2576-E.2021. 133. Cravero K, Pantone MV, Shin DH, Bergman R, Cochran R, Chu D, Zabransky DJ, Karthikeyan S, Waters IG, Hunter N, Rosen DM, Kyker-Snowman K, Dalton WB, Button B, Shinn D, Wong HY, Donaldson J, Hurley PJ, Croessmann S, Park BH. NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. Oncotarget. 2022 Feb 16;13:373-386. 134. Lavery JA, Lepisto EM, Brown S, Rizvi H, McCarthy C, LeNoue-Newton M, Yu C, Lee J, Guo X, Yu T, Rudolph J, Sweeney S; AACR Project GENIE Consortium, Park BH, Warner JL, Bedard PL, Riely G, Schrag D, Panageas KS. A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. JCO Clin Cancer Inform. 2022 Feb;6:e2100105. 135. Zuo Q, Mogol AN, Liu YJ, Santaliz Casiano A, Chien C, Drnevich J, Imir OB, Kulkoyluoglu-Cotul E, Park NH, Shapiro DJ, Park BH, Ziegler Y, Katzenellenbogen BS, Aranda E, O'Neill JD, Raghavendra AS, Tripathy D, Madak Erdogan Z. Targeting metabolic adaptations in the breast cancer-liver metastatic niche using dietary approaches to improve endocrine therapy efficacy. Mol Cancer Res. 2022 Feb 23. 136. Liu MC, MacKay M, Kase M, Piwowarczyk A, Lo C, Schaeffer J, Finkle JD, Mason CE, Beaubier N, Blackwell KL, Park BH. Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. JCO Precis Oncol. 2022 Jun 6;6(1):e2100321. 137. Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 Jun 27. 138. Udden SN, Wang Q, Kumar S, Malladi VS, Wu SY, Wei S, Posner BA, Geboers S, Williams NS, Liu YL, Sharma JK, Mani RS, Malladi S, Parra K, Hofstad M, Raj GV, Larios JM, Jagsi R, Wicha MS, Park BH, Gupta GP, Chinnaiyan AM, Chiang CM, Alluri PG. Targeting ESR1 mutation-Induced transcriptional addiction in breast cancer with BET inhibition. JCI Insight. 2022 Jul 26;e151851. Peer reviewed invited review articles 1. Park BH, Breyer B, He TC. Peroxisome Proliferator-Activated Receptors: Roles in Tumorigenesis and Chemoprevention in Human Cancer. Current Opinion in Oncology 13:78-83, 2001. 2. Bachman KE, Park BH. The ‘Duel’ nature of TGF-beta signaling: tumor suppressor vs. tumor promoter, review, Current Opinion in Oncology, vol. 17, pp.49-54, Jan. 2005. 3. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers, review, Br J Cancer, 94(4):455-9, Feb 27, 2006. 4. Abukhdeir A, Park BH. p21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008 Jul 1;10:e19. 5. Gustin JP, Cosgrove D, Park BH. The PIK3CA gene as a mutated target for cancer therapy, Current Cancer Drug Targets, Dec;8(8):733-40, 2008. 6. Wang GM, Park BH. The Role of PIK3CA Mutations as a Predictor of Outcomes and a Therapeutic Target. Current Breast Cancer Reports, 2(4):167-173, 2010. 7. Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment, Clinical and Experimental Metastasis, Jun 13, 2012. 8. Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer, Am J Ca Research, 2(4):434-45, 2012. 9. Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy, J Mammary Gland Biol Neoplasia, Dec;17(3-4):205-16, 2012. 10. Croessmann S, Cidado J, Gustin JP, Cosgrove D, Park BH. The PIK3CA gene as a mutated target for cancer therapy, Advances in Cancer Drug Targets, 2013. 11. Blair B, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies, The Journal of Pathology, Jan;232(2):244-54, 2014. 12. Christenson E., James T., Agrawal V., Park BH. Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity, Clinical Biochemistry, Mar;48(4-5):223-35, 2015. 13. Cravero K and Park BH. Circulating Tumor DNA—the Potential of Liquid Biopsies. Curr Breast Cancer Rep, 8 (1), 14-21, 2016. 14. Canzoniero JV and Park BH. Use of cell free DNA in breast oncology. BBA - Reviews on Cancer. Apr;1865(2):266-74, 2016. 15. Button B and Park BH. ESR1 mutations: Pièce de résistance. Genes and Diseases. 3 (2), 124-129, 2016. 16. Chu D and Park BH. Liquid Biopsy: Unlocking the Potentials of Cell Free DNA. Virchows Archives. In press, 2017. 17. Donaldson J and Park BH. Circulating Tumor DNA: Measurement and Clinical Utility. Annu Rev Med. 2017 Aug 28. 18. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. Sep 28,2018. 19. Croessmann S and Park BH. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Clin Adv Hematol Oncol. 2021 Mar;19(3):155-161. 20.Davidson BA, Croessmann S, Park BH. The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer. Br J Cancer. 2021 2021 Sep;125(6):780-788. 21.Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022 Jun 15;132(12):e154941.
Peer review invited commentaries/editorials 1. Park BH, Davidson N. Estrogen Receptor Status. Cell Cycling and Paclitaxel: Looking for a “Hormone”-ious Explanation, Cancer Biology and Therapy, 3:468-469, 2004. 2. Park BH, Davidson N. PI3 Kinase activation and response to Trastuzumab therapy: What’s neu with Herceptin resistance? Cancer Cell, Oct;12(4):297-9, 2007. 3. Higgins MJ, Park BH. Expanding role of bisphosphonates in the management of early breast cancer. Expert Rev Anticancer Ther. Aug;9(8):1051-4. 2009. 4. Mohseni M, Park BH. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001. Journal of Clinical Investigation, Aug 2;120(8):2655-8, 2010. 5. Jelovac D, Park BH. PTEN Promoter Silencing and Cowden Syndrome. JAMA, 304(24):2744-2745, 2010. 6. Lauring J, Park BH. BEAMing shines a light on drug resistance. Clinical Cancer Research, Dec 15; 17(24):7508-10, 2011. 7. Beaver J, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor positive advanced breast cancer. Future Oncology, 8(6):651-7, 2012. 8. Cidado J, Beaver J, Park BH. Needles in a haystack: finding recurrent genomic changes in breast cancer. Breast Cancer Research, Feb 19;14(1):304, 2013. 9. Cochran R, Lauring J, Park BH. TORn in Two Over Breast Cancer Drug Resistance. Oncology, 27 (1), 2013. 10. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw, Jun 1;11(6):670-8, 2013. 11. Wong HY, Park BH. Plasma tumor DNA: On your mark-ers, get set, GO! Annals of Translational Medicine, Vol 2, 1, Jan. 2014. 12. Zabransky, DJ and Park BH. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. J Clin Oncol. Apr 1;32(10):1084-6, 2014. 13. Stearns V and Park BH. Gene mutation profiling of breast cancers for clinical decision making: drivers and passengers in the cart before the horse. JAMA Oncology, Aug;1(5):569-70, 2015. 14. Beaver, JA and Park BH. “Detecting plasma tumor DNA in early stage breast cancer - Reply,” Clinical Cancer Research, Aug 1;21(15):3570, 2015. 15. Stearns V and Park BH. PIK3CA Mutations in Hormone Receptor–Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions. JAMA Oncology, Published online June 14, 2018 16. Graham M, Park BH and Wyhs N. Personalized Postdoctoral Fellowship Care. Nature Biotechnology, Sep 6;36(9):900-902. 2018. 17. Karthikeyan S, Park BH. Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer-Bad Blood. JAMA Oncol. 2019 Aug 1. 18. Croessmann S, Park BH. Variant Interpretation in Patients With Metastatic Breast Cancer-Reply. JAMA Oncol. 2020 Jan 30.
Book Chapters 1. Park BH, Vogelstein B. “Tumor Suppressor Genes”, in Cancer Medicine, 6th ed. Holland and Frei editors. BC Decker, Hamilton Ontario, 2003. 2. Park BH, Vogelstein B. “Tumor Suppressor Genes”, in Cancer Medicine, 7th ed. Holland and Frei editors. BC Decker, Hamilton Ontario, 2006. 3. Park BH. “PIK3CA Oncogene”, in Encyclopedia of Cancer, 2nd ed. M. Schwab editor. Springer, 2008. 4. Park BH. Faculty Reviewer, “First Aid for the USMLE Step 2, Clinical Knowledge,” seventh edition, McGraw Hill, 2009. 5. Cosgrove D, Vogelstein B, Park BH. “Tumor Suppressor Genes,” in Cancer Medicine, 8th ed. Holland and Frei editors. BC Decker, Hamilton Ontario, 2010. (Due to an editorial error Dr. Park is listed as 2nd author). 6. Beaver J, Park BH. “Circulating cell-free DNA for molecular diagnostics and therapeutic monitoring” in Genome Applications in Biology, 85-97, Springer, 2015. 7. Cosgrove D, Park BH, Vogelstein B, “Tumor Suppressor Genes,” in Cancer Medicine, 9th ed. Holland and Frei editors. Wiley, 2016. 8. Parsons, H, Beaver J and Park BH. "Circulating Plasma Tumor DNA” in Novel Biomarkers in the Continuum of Breast Cancer, Stearns editor. Volume 882 of the series Advances in Experimental Medicine and Biology pp 259-276 Springer, 2016. 9. Kyker-Snowman K, Park BH. “Circulating Free Tumor DNA (ctDNA): The Real-Time Liquid Biopsy” Liquid Biopsies in Solid Tumors, pp 105-118, Springer, 2017. 10. Medford A, Gillani R and Park BH. “Detection of Cancer DNA in Plasma of Early Stage Breast Cancer Patients”, in Digital PCR Applied Protocols, Methods in Molecular Biology, Karlin-Neumann and Bizouarn editors, Springer, in press, 2018. 11. Hunter TB, Beaver JA and Park BH. “Circulating cell-free DNA for molecular diagnostics and therapeutic monitoring” in Genome Applications in Biology, 2nd Ed., Springer, in press, 2017. 13.Park BH. “Cancer Biology and Genetics”, Goldman-Cecil Medicine, 26th Edition, 2019. 14.Park BH. “Cancer Biology and Genetics”, Goldman-Cecil Medicine, 27th Edition, 2022.
Other media 1. Shockney L, Park BH, Health Monitor “Guide 2 Chemo,” http://www.guide2chemo.com/ 2009.
